Opsona Therapeutics was a drug development company specialising in the human immune system and new drugs and vaccines to prevent and treat autoimmune/inflammatory conditions, cancers and infectious diseases.
Based in Ireland, Opsona was a spin-out from Trinity College Dublin (TCD). Ireland is ranked highly in the world in immunology research, and TCD has been at the forefront of the field.Times Higher Education Supplement - QS World University Rankings 2007
Opsona's research was primarily focused on the role of Toll-like receptors (TLRs) and TLR signalling in human innate immunity. The company was founded in 2004 by three immunologists:
Professor Luke O'Neill Professor Kingston Mills Professor Dermot P. Kelleher
The company went into liquidation in 2019 after unsuccessful clinical trials, and failure to find a buyer for OPN-305.
Opsona's main investors were international and life-science focused:
Inventages Venture Capital (Bahamas) Seroba Bioventures (Ireland) GenenFund (United States) Enterprise Ireland (Ireland)
References